Analysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) PT at $34.89

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has received an average recommendation of “Hold” from the twenty-two research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eighteen have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $35.7222.

Several equities research analysts have weighed in on the company. The Goldman Sachs Group reiterated a “sell” rating and issued a $19.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Wedbush decreased their target price on Apellis Pharmaceuticals from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Wall Street Zen cut shares of Apellis Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Saturday, February 28th. Citigroup reissued a “neutral” rating and set a $41.00 price objective (down from $44.00) on shares of Apellis Pharmaceuticals in a research report on Wednesday, April 1st. Finally, Royal Bank Of Canada decreased their price objective on shares of Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of APLS. Wedmont Private Capital grew its holdings in shares of Apellis Pharmaceuticals by 4.1% during the 4th quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock worth $315,000 after acquiring an additional 468 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Apellis Pharmaceuticals by 0.6% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 96,125 shares of the company’s stock valued at $2,415,000 after purchasing an additional 530 shares in the last quarter. Amalgamated Bank boosted its position in shares of Apellis Pharmaceuticals by 6.9% during the third quarter. Amalgamated Bank now owns 8,674 shares of the company’s stock valued at $196,000 after purchasing an additional 563 shares in the last quarter. Xponance LLC grew its stake in Apellis Pharmaceuticals by 3.9% in the fourth quarter. Xponance LLC now owns 18,164 shares of the company’s stock worth $456,000 after purchasing an additional 681 shares during the period. Finally, Allworth Financial LP raised its holdings in Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after purchasing an additional 857 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $41.02 on Tuesday. The company’s fifty day simple moving average is $31.12 and its two-hundred day simple moving average is $25.78. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $41.14. The firm has a market cap of $5.25 billion, a PE ratio of 40.22 and a beta of -0.24. The company has a quick ratio of 3.16, a current ratio of 3.63 and a debt-to-equity ratio of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.44. The firm had revenue of $268.30 million during the quarter, compared to the consensus estimate of $208.91 million. Apellis Pharmaceuticals had a net margin of 12.06% and a return on equity of 39.71%. As a group, equities analysts expect that Apellis Pharmaceuticals will post -1.23 EPS for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.